Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial

被引：0

作者：

Masip, J. Remon ^{[1
]}

Besse, B. ^{[1
]}

Aix, S. Ponce ^{[2
]}

Perez, A. Callejo ^{[3
]}

Al-Rabi, K. ^{[4
]}

Caro, R. Bernabe ^{[5
]}

Greillier, L. ^{[6
]}

Tarruella, M. Majem ^{[7
]}

Aransay, N. Reguart ^{[8
]}

Monnet, I. ^{[9
]}

Cousin, S. ^{[10
]}

Lopez, P. Garrido ^{[11
]}

Robinet, G. ^{[12
]}

Campelo, R. Garciaprime ^{[13
]}

Flandin, A-C. Madroszyk ^{[14
]}

Mazieres, J. ^{[15
]}

Curcio, H. ^{[16
]}

Pretzenbacher, Y. ^{[17
]}

Dingemans, A-M. C. ^{[18
]}

Dziadziuszko, R. ^{[19
]}

机构：

[1] Inst Gustave Roussy, Oncol Dept, Villejuif, France

[2] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[3] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain

[4] KHCC King Hussein Canc Ctr, Med Oncol & Hematol Dept, Amman, Jordan

[5] Hosp Univ Virgen Rocio, Seville, Spain

[6] Hop St Marguerite Assistance Publ Hop Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France

[7] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[8] Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain

[9] Chi Creteil, Creteil, France

[10] Inst Bergonie, Early Phase Trials, Bordeaux, France

[11] Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain

[12] CHRU Brest Hop Morvan, Brest, France

[13] CHUAC Complexo Hosp Univ A Coruna, La Coruna, Spain

[14] IPC Inst Paoli Calmettes, Marseille, France

[15] Ctr Hosp Univ Toulouse, Thorac Oncol Dept, Hop Larrey, Toulouse, France

[16] Ctr Francois Baclesse, Oncol Dept, Caen, France

[17] EORTC AISBL IVZW European Org Res & Treatment Can, Stat, Brussels, Belgium

[18] Erasmus MC Univ, Pulmonol Dept, Med Ctr, Rotterdam, Netherlands

[19] Med Univ Gdansk, Oncol & Radiotherapy Dept, Gdansk, Poland

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S35 / S35

页数：1

共 50 条

[1] Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
Remon, Jordi
Besse, Benjamin
Aix, Santiago Ponce
Callejo, Ana
Al-Rabi, Kamal
Bernabe, Reyes
Greillier, Laurent
Majem, Margarita
Reguart, Noemi
Monnet, Isabelle
Cousin, Sophie
Garrido, Pilar
Robinet, Gilles
Campelo, Rosario Garcia
Madroszyk, Anne
Mazieres, Julien
Curcio, Hubert
Wasag, Bartosz
Pretzenbacher, Yassin
Grillet, Fanny
Dingemans, Anne-Marie C.
Dziadziuszko, Rafal
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (12) : 1350 - 1356
[2] Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Masip, J. Remon
Besse, B.
Ponce Aix, S.
Callejo, A.
Al-Rabi, K.
Bernabe Caro, R.
Greillier, L.
Majem Tarruella, M.
Reguart Aransay, N.
Monnet, I.
Cousin, S.
Lopez, P. Garrido
Robinet, G.
Garcia Campelo, M. R.
Flandin, A-C. Madroszyk
Mazieres, J.
Pretzenbacher, Y.
Fournier, B.
Dingemans, A-M. C.
Dziadziuszko, R.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1419 - S1419
[3] CARDIOVASCULAR EVENTS IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER ON OSIMERTINIB
Peleg, Ariel
Ibtida, Ishmam
Liu, Jennifer
Steingart, Richard
Yu, Anthony
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3288 - 3288
[4] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
Blaquier, Juan Bautista
Ortiz-Cuaran, Sandra
Ricciuti, Biagio
Mezquita, Laura
Cardona, Andres Felipe
Recondo, Gonzalo
CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
[5] Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Kim, C.
Liu, S.
Subramaniam, D.
Giaccone, G.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S479 - S479
[6] Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Remon, J.
Besse, B.
Aix, S. Ponce
Callejo, A.
Al-Rabi, K.
Bernabe, R.
Greillier, L.
Majem, M.
Reguart, N.
Monnet, I.
Cousin, S.
Garrido, P.
Robinet, G.
Campelo, R. Garcia
Madroszyk, A.
Mazieres, J.
Curcio, H.
Wasag, B.
Pretzenbacher, Y.
Fournier, B.
Dingemans, A. -M. C.
Dziadziuszko, R.
ANNALS OF ONCOLOGY, 2023, 34 (05) : 468 - 476
[7] Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
Tozuka, Takehiro
Noro, Rintaro
Mizutani, Hideaki
Kurimoto, Futoshi
Hakozaki, Taiki
Hisakane, Kakeru
Naito, Tomoyuki
Takahashi, Satoshi
Taniuchi, Namiko
Yajima, Chika
Hosomi, Yukio
Hirose, Takashi
Minegishi, Yuji
Okano, Tetsuya
Kamio, Koichiro
Yamaguchi, Tomoyoshi
Seike, Masahiro
LUNG CANCER, 2024, 191
[8] Osimertinib in EGFR-mutant non-small cell lung carcinoma
Lorenz, Judith
PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
[9] Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer
Chen, Lanyi Nora
Ma, Xin
Herzberg, Benjamin
Henick, Brian S.
Biswas, Anup K.
Acharyya, Swarnali
Shu, Catherine A.
ONCOLOGIST, 2024,
[10] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Ortega-Franco, Ana
Rafee, Shereen
ONCOLOGY AND THERAPY, 2022, 10 (01) : 13 - 22

← 1 2 3 4 5 →